The Japanese Health Ministry is set to approve the antiviral drug today.
The Japanese health minister stated Tuesday that he is looking to authorize Remdesivir as a treatment against the novel virus if it is approved beforehand by an advisory panel. Gilead, the company which trials the drug, applied for approval this Monday.
Japan's move comes almost a week after the drug received the green light on Friday, May 1st, in the US. It will be used against severe cases only. The US approval came after clinical trials showed a shorting by a third in patients’ recovery time. The treatment will be administrated by injection. During Monday's trading session, Gilead's stock price dropped by 0.36%.
The move is unexpected, as the Japanese approval process usually takes a year, and it based on domestic clinical trials. The expectations are high, as using Remdesivir was already on the table since late April.
The use of Remdesivir is quite controversial, as it previously underwent clinical trials against Ebola, but it performed much worse than other drugs. Nevertheless, it is put against COVID-19 because it can disable the virus's mechanism of copying itself to submerge the host's immune system.
The latest data released by the New England Journal of Medicine shows a drug effectiveness of 70% of 53 patients with severe symptoms. Although effective, the side effects were severe – deterioration of kidney and liver functions, which occurred in a quarter of patients.
Not only Remdesivir is looking for approval this month, but also Avigan – a locally developed drug by Fujifilm Toyama Chemical. If the 100 patients trial test will be validated, the drug will be approved later this month.
Avigan, commonly known as Favipiravir, was already approved in 2014 but only as a drug against the flu outbreaks. It is typically available only by demand from the Japanese government. When administrated, it blocks the virus’ ability to replicate itself inside a cell. If Remdesivir affects kidneys and liver, Avigan is counter indicated to pregnant women as animal studies showed that it influences fetal development.
See the difference when trading with CAPEX.com by accessing elite features:
- Stellar custom service
- Powerful WebTrader platform and mobile app
- High-end integrated trading tools
- Full license and regulation from top regulators
Sources: forexfactory.com, bnnbloomberg.ca, thestreet.com, france24.com
The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation. Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.
Użytkownicy / czytelnicy nie powinni polegać wyłącznie na informacjach przedstawionych w niniejszym dokumencie i powinni przeprowadzać własne badania / analizy, czytając również rzeczywiste badania bazowe. Treść jest ogólna i nie uwzględnia indywidualnych okoliczności osobistych, doświadczenia inwestycyjnego ani aktualnej sytuacji finansowej.
Key Way Investments Ltd nie ma wpływu ani nie ma żadnego wkładu w formułowanie informacji zawartych w niniejszym dokumencie. Treść jest ogólna i nie uwzględnia indywidualnych okoliczności osobistych, doświadczenia inwestycyjnego ani aktualnej sytuacji finansowej.